| Home | E-Submission | Sitemap | Editorial Office |  
top_img
Clinical and Molecular Hepatology Search > Browse Articles > Search



Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line
Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti
Clin Mol Hepatol.2020;26(1):45-53.   Published online September 30, 2019     
DOI: https://doi.org/10.3350/cmh.2019.0031
                              Supplementary      
Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review
Tae Suk Kim, Ji Hoon Kim, Baek hui Kim, Young-Sun Lee, Yang Jae Yoo, Seong Hee Kang, Sang-June Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
Clin Mol Hepatol.2017;23(4):340-346.   Published online June 20, 2017     
DOI: https://doi.org/10.3350/cmh.2016.0070
                                 Cited By 4
A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function
Hyun Yang, Hyun Young Woo, Soon Kyu Lee, Ji Won Han, Bohyun Jang, Hee Chul Nam, Hae Lim Lee, Sung Won Lee, Do Seon Song, Myeong Jun Song, Jung Suk Oh, Ho Jong Chun, Jeong Won Jang, Angelo Lozada, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Clin Mol Hepatol.2017;23(2):128-137.   Published online May 10, 2017     
DOI: https://doi.org/10.3350/cmh.2016.0071
                              Supplementary         Cited By 10
Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?
Do Young Kim
Clin Mol Hepatol.2017;23(2):123-124.   Published online June 23, 2017     
DOI: https://doi.org/10.3350/cmh.2017.0107
                              
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis
Jung Min Lee, Byoung Kuk Jang, Yoo Jin Lee, Wang Yong Choi, Sei Myong Choi, Woo Jin Chung, Jae Seok Hwang, Koo Jeong Kang, Young Hwan Kim, Anil Kumar Chauhan, Soo Young Park, Won Young Tak, Young Oh Kweon, Byung Seok Kim, Chang Hyeong Lee
Clin Mol Hepatol.2016;22(1):160-167.   Published online March 28, 2016     
DOI: https://doi.org/10.3350/cmh.2016.22.1.160
                                 Cited By 29
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
Jung Gil Park
Clin Mol Hepatol.2015;21(3):287-294.   Published online September 30, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.3.287
                                 Cited By 17
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells
Ha Ra Gu, Su Cheol Park, Su Jin Choi, Jae Cheol Lee, You Cheoul Kim, Chul Ju Han, Jin Kim, Ki Young Yang, Yeon Joo Kim, Geum Youb Noh, So Hyeon No, Jae-Hoon Jeong
Clin Mol Hepatol.2015;21(1):49-59.   Published online March 25, 2015     
DOI: https://doi.org/10.3350/cmh.2015.21.1.49
                                 Cited By 14
Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib
Joon-Il Choi, David K Imagawa, Priya Bhosale, Puneet Bhargava, Temel Tirkes, Tara E Seery, Chandana Lall
Clin Mol Hepatol.2014;20(2):218-222.   Published online June 30, 2014     
DOI: https://doi.org/10.3350/cmh.2014.20.2.218
                                 Cited By 3
The effect of sorafenib on hepatic stellate cells: implication of its effect on tumor microenvironment
Jung Il Lee
Korean J Hepatol.2010;16(4):418-419.   Published online December 31, 2010     
DOI: https://doi.org/10.3350/kjhep.2010.16.4.418
                                 Cited By 1
Molecular targeting for treatment of advanced hepatocellular carcinoma
Il Han Song
Korean J Hepatol.2009;15(3):299-308.   Published online September 30, 2009     
DOI: https://doi.org/10.3350/kjhep.2009.15.3.299
         Cited By 6
The Korean Journal of Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma
Jeong Heo
Korean J Hepatol.2009;15(2):227-230.   Published online June 30, 2009     
DOI: https://doi.org/10.3350/kjhep.2009.15.2.227
      
The Korean Journal of The Efficacy of Sorafenib for Patients With Advanced Hepatocellular Carcinoma
Jeong Heo
Korean J Hepatol.2007;13(4):576-580.   Published online December 20, 2007     
DOI: https://doi.org/10.3350/kjhep.2007.13.4.576
      
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
Sadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato
Received November 15, 2019     Accepted November 22, 2019     Published online January 15, 2020     
DOI: https://doi.org/10.3350/cmh.2019.0021n    
[Epub ahead of print]
      
1 |
E-Submission
Email Alert
Author's Index
EndNote Style file download
The Korean Association for the Study of the Liver
The Liver Week 2019
SCImago Journal & Country Rank
PubMed Central
PubMed
Scopus
KoreaMed
KoMCI
ScienceCentral
DOAJ
GoogleScholar
Similarity Check
Crossref Cited-by Linking
CrossMark
Funder Registry
ORCID
MeSH on Demand
COPE
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association for the Study of the Liver. All rights reserved.         
COUNTER
TODAY : 286
TOTAL : 295456